

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,  
INNOPHARMA INC., INNOPHARMA LLC,  
MYLAN PHARMACEUTICALS INC., and MYLAN INC.,  
Petitioner,

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and  
BAUSCH & LOMB PHARMA HOLDINGS CORP.  
Patent Owner.

---

Case IPR2015-00902 (Patent 8,669,290 B2)  
Case IPR2015-00903 (Patent 8,129,431 B2)<sup>1</sup>

---

**PETITIONER'S NOTICE OF CROSS-EXAMINATION OF  
SHIROU SAWA**

---

<sup>1</sup> A word-for-word identical paper has been filed in each proceeding identified in the heading. IPR2015-01871 has been joined with IPR2015-00903 and includes Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc. in addition to the parties identified above.

Pursuant to 37 C.F.R. § 42.53, Petitioners INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and MYLAN INC., (“Petitioner” or “InnoPharma”), by and through its attorneys, will conduct a cross-examination by deposition of Shirou Sawa regarding his declarations submitted in IPR2015-00902 and IPR2015-00903. Mr. Sawa’s cross-examination will take place, as agreed by counsel for the parties, on March 1, 2016, commencing at 9:00 a.m. (local time), at the offices of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC 20001-4413. Counsel for Patent Owner has represented that Mr. Sawa is willing to appear at the time and location indicated above.

The cross-examination will take place before a Notary Public or other officer authorized by law to administer oaths. It will be recorded using at least audiotape and/or stenographic means. InnoPharma also intends to video record the cross-examination of Mr. Sawa. The arrangements for the reporter and videographer will be made by counsel for Petitioners. Counsel for Patent Owner has notified that Mr. Sawa will require an interpreter, thus Petitioner will initiate a conference with the Board pursuant to 37 C.F.R. § 42.53(e) in due course.

Date: January 29, 2016

*/Jitendra Malik/*

Case IPR2015-00902 (Patent 8,669,290 B2)

Case IPR2015-00903 (Patent 8,129,431 B2)

Jitendra Malik (Reg. No. 55823)

**Alston & Bird LLP**

4721 Emperor Boulevard, Suite 400

Durham, North Carolina 27703

Telephone: 919-862-2200

Fax: 919-862-2260

Jitty.Malik@alston.com

*Lead Counsel for Petitioner*

*InnoPharma Licensing Inc., InnoPharma*

*Licensing LLC, InnoPharma Inc.,*

*InnoPharma LLC, Mylan*

*Pharmaceuticals Inc., and Mylan Inc.*

**CERTIFICATION OF SERVICE**

The undersigned certifies that on the 29th day of January, 2016, a copy of the foregoing Petitioner's Notice of Cross-Examination of Shirou Sawa was served via email directed to counsel of record for the Patent Owner and counsel of record for Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc. at the following:

**Patent Owner**

Bryan C. Diner  
bryan.diner@finnegan.com

Justin J. Hasford  
justin.hasford@finnegan.com

Joshua L. Goldberg  
Joshua.goldberg@finnegan.com

**Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc.**

Deborah H. Yellin  
DYellin@Crowell.com

Jonathan Lindsay  
JLindsay@Crowell.com

Respectfully submitted,

Alston & Bird LLP

By: /Jitendra Malik/

Jitendra Malik, Ph.D.  
Reg. No. 55823  
Alston & Bird LLP  
4721 Emperor Blvd., Suite 400  
Durham, NC 27703-8580

Case IPR2015-00902 (Patent 8,669,290 B2)

Case IPR2015-00903 (Patent 8,129,431 B2)

[jitty.malik@alston.com](mailto:jitty.malik@alston.com)

Bryan Skelton, Ph.D.

Reg. No. 50893

Alston & Bird LLP

4721 Emperor Blvd., Suite 400

Durham, NC 27703-8580

[bryan.skelton@alston.com](mailto:bryan.skelton@alston.com)

Lance Soderstrom

Reg. No. 65405

Alston & Bird LLP

90 Park Avenue

15<sup>th</sup> Floor

New York, NY 10016-1387

[lance.soderstrom@alston.com](mailto:lance.soderstrom@alston.com)

Hidetada James Abe

Reg. No. 61,182

Alston & Bird LLP

333 South Hope Street

16th Floor

Los Angeles, CA 90071

[james.abe@alston.com](mailto:james.abe@alston.com)

*Attorneys for Petitioners InnoPharma  
Licensing, Inc., InnoPharma Licensing LLC,  
InnoPharma Inc., InnoPharma LLC, Mylan  
Pharmaceuticals Inc., and Mylan Inc.*